- Novo Nordisk
- Merck & Co., Inc
- Eli Lilly and Company
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd
- Novartis AG
- AnkeBio Co. Ltd
- F. Hoffmann-La Roche
- Ipsen
- Ferring BV
- GeneScience Pharmaceuticals Co, Ltd
- Biopartners GMBH
- Zhongshan Hygene Biopharma Co, Ltd
- Lifetech Labs
- EMD Serono Inc.
(Note: The list of the major players will be updated with the latest market scenario and trends)
Recent developments by key players in Human Growth Hormone Market:
- In February 2021- To assess the effectiveness and safety of somatropin in a cohort of Japanese individuals with Prader-Willi Syndrome (PWS), Pfizer Inc. started Phase III clinical research.
The prevalence of chronic diseases, growth retardation, and illnesses caused by pituitary gland dysfunction are a few factors anticipated to contribute to the significant rise of the human growth hormone market throughout the forecast year. Over the past few years, hormonal abnormalities such as Turner syndrome, idiopathic short stature, Laron syndrome, septo-optic dysplasia, acromegaly, and Noonan syndrome have become more prevalent due to significant lifestyle changes, among other factors. As a result, there is now a higher demand for medications and food supplements that include synthetic HGH, propelling the market's expansion. The regulatory approvals for the commercial and medical uses of HGH, the increasing focus on monitoring the overall development of the fetus, the increasing prevalence of skeletal abnormalities, pituitary tumors, neuropsychiatric-cognitive disorders, neuromuscular and metabolic abnormalities, rising disposable income, and rising healthcare spending are all expected to contribute to the growth of the human growth hormone market. Moreover, congenital ovarian hypoplasia syndrome, often known as Turner syndrome, is when a woman lacks all or a portion of her X chromosome. Turner syndrome (TS) is humans' most frequent chromosomal defect, occurring in 1:2,500 live births. Human growth hormones assist in growth, reproduction, and regeneration. Increased growth hormone use and awareness, which help treat diseases brought on by hormonal imbalance, promote market expansion. Other factors, such as increased awareness of treatment options, a rise in health problems, and a rise in neuropsychiatric cases, are also expected to favorably impact the market for human growth hormones. However, the costs of the R&D required for human growth hormones are extremely high. The high cost of treatment is another issue preventing the market for human growth hormones from expanding. The negative effects of recombinant human growth hormones, such as sore joints and muscles, leg and arm swelling, increased insulin resistance, and carpal tunnel syndrome, are also projected to hinder the growth of the human growth hormone market.